Development of a blood or urine test to improve treatments for Hodgkin's Lymphoma.
Identifying molecules in blood or urine that predict the effectiveness of treatments for Hodgkin’s Lymphoma will allow improved treatments to be given to patients.
Hodgkin’s Lymphoma is cancer arising from white blood cells. As white blood cells are part of the immune system, patients are more susceptible to infections. The NHS states that it is one of the most easily treated types of cancer. Still, about 15% of patients treated for Hodgkin’s Lymphoma fail to respond to treatment, or the cancer will return. These patients often require more intense chemotherapy, and the dosage has to be balanced with toxicity and side effects. Being able to predict the effectiveness of treatments for individuals would enable those that may have poor outcomes to receive more intense treatment. A current approach is by PET-CT scanning. However it is expensive to operate and requires an expert to interpret the results.
Taking a blood or urine test to give information on Hodgkin’s Lymphoma
This project will focus on developing a relatively simple blood or urine test, which will be easier and more cost effective to carry out than a PET-CT scan. A “state of the art” analytical technique known as high-resolution nuclear magnetic resonance (NMR) spectroscopy will be used. It can rapidly monitor hundreds of molecules in body fluid samples and identify molecules that are reliable indicators of the future course and outcome of patients with Hodgkin’s Lymphoma. Information about the development and progression of disease may also be inferred from the results. This will help in the development of new treatments for this condition.
This award of £35,000 was awarded to De Montfort University’s School of Pharmacy.
More information (links open in a new tab):